文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

南非HIV-1患者中替诺福韦与阿巴卡韦联合胞嘧啶类似物及多替拉韦的预测抗病毒活性比较

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究在南非治疗即预防研究中,对1193例ART初治者和94例已接受ART者进行HIV-1 pol基因NGS检测,比较替诺福韦或阿巴卡韦联合胞嘧啶类似物及多替拉韦的预测活性。结果显示初治者NRTI耐药突变率低,已治疗者中替诺福韦与阿巴卡韦敏感性差异无统计学意义。

要点

  • 初治者NRTI耐药突变(20%阈值)仅0.4%,5%阈值0.8%。
  • 已治疗者中替诺福韦与阿巴卡韦敏感性差异无统计学意义(P=0.16和0.29)。
  • NGS 5%阈值可提高K65R突变检出。

核心结论

  • 在南非ART初治者中,多替拉韦联合胞嘧啶类似物加替诺福韦或阿巴卡韦的预测疗效相似。

研究设计与样本

  • 研究嵌套于南非治疗即预防研究,选取有HIV-1 pol基因NGS数据的1287例参与者(初治者1193例,已治疗者94例),使用MiSeq技术检测5%和20%阈值的耐药突变,并用Stanford HIVDB算法评估基因型敏感性。

主要发现

  • 初治者中NRTI耐药突变20%阈值检出5/1193(0.4%),5%阈值检出9/1193(0.8%)。
  • 已治疗者中73/94(77.7%)有替诺福韦暴露史;对阿巴卡韦完全敏感者分别为57/94(60.6%,20%阈值)和56/94(59.6%,5%阈值);对替诺福韦完全敏感者分别为67/94(71.3%,20%阈值)和64/94(68.1%,5%阈值)。
  • 替诺福韦与阿巴卡韦敏感性差异在20%阈值(P=0.16)和5%阈值(P=0.29)均无统计学意义。
  • 5%阈值NGS检测在初治和已治疗组均增加了K65R的检出。
  • 607条整合酶序列中仅1条携带20%阈值的耐药突变(Q148R)。

临床怎么用

  • 在南非等资源有限地区,多替拉韦联合胞嘧啶类似物加替诺福韦或阿巴卡韦均可作为初治方案选择。
  • NGS用于HIV耐药监测可提高低丰度耐药突变的检出。

局限性

  • 已治疗者样本量较小(94例),可能影响统计效能。
  • 预测活性基于基因型敏感性算法,未直接评估临床病毒学应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The WHO recently recommended the use of a new first-line ART containing dolutegravir. We investigated the efficacy of NRTI backbones (tenofovir or abacavir with a cytosine analogue) in low- and middle-income countries where there is significant prior exposure to antiretrovirals and drug resistance to NRTIs. METHODS: Within the treatment-as-prevention study in South Africa, we selected participants with available next-generation sequencing (NGS) data for the HIV-1 pol gene at trial entry; they were either ART initiators (n = 1193) or already established on ART (n = 94). NGS of the HIV-1 pol gene was carried out using MiSeq technology; reverse transcriptase drug resistance mutations (DRMs) were detected at 5% (DRM5%) and 20% (DRM20%) for all 1287 participants. Genotypic susceptibility was assessed using the Stanford HIVDB resistance interpretation algorithm. RESULTS: NRTI DRM20% and DRM5% were detected among 5/1193 (0.4%) and 9/1193 (0.8%) of ART initiators, respectively. There was tenofovir exposure in 73/94 (77.7%) of those established on ART, with full susceptibility to abacavir in 57/94 (60.6%) and 56/94 (59.6%) for DRM20% and DRM5%, respectively, while 67/94 (71.3%) and 64/94 (68.1%) were fully susceptible to tenofovir, respectively. The differences between tenofovir and abacavir were not statistically significant at the 20% or 5% variant level (P = 0.16 and 0.29, respectively). NGS detection of variants at the 5% level increased detection of K65R in both naive and treated groups. One of 607 integrase sequences carried a DRM20% (Q148R). CONCLUSIONS: Dolutegravir with a cytosine analogue plus tenofovir or abacavir appears to have similar efficacy in South Africans naive to ART. NGS should be considered in HIV drug resistance surveillance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Derache A, Iwuji CC, Danaviah S, et al. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. J Antimicrob Chemother. 2019. PMID: 30380053. doi:10.1093/jac/dky428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。